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24 Abstract
25 Objective: TSG-6 is an anti-inflammatory protein highly expressed in osteoarthritis (OA), but 
26 its influence on the course of OA is unknown.
27 Methods: Cartilage injury was assessed by murine hip avulsion or re-cutting rested explants. 
28 42 previously validated injury genes were quantified by real-time PCR in whole joints post 
29 DMM (6h and 7days). Joint pathology was assessed 8 and 12 weeks following destabilisation 
30 of the medial meniscus (DMM) in 10 week old male and female FGF2-/-, TSG-6-/-, TSG-6tg 
31 (overexpressing), FGF2-/-;TSG-6tg (8 weeks only) mice and strain-matched, wild type controls. 
32 In vivo cartilage repair was assessed 8 weeks following focal cartilage injury in TSG-6tg and 
33 control mice. FGF2 release following cartilage injury was measured by ELISA. 
34
35 Results: TSG-6 mRNA upregulation was strongly FGF2-dependent upon injury in vitro and in 
36 vivo. 15 inflammatory genes were significantly increased in TSG-6-/- joints including IL1α, 
37 Ccl2 and Adamts5 compared with wild type. Six genes were significantly suppressed in TSG-
38 6-/- joints including Timp1, Inhibin βA and podoplanin (known FGF2 target genes). FGF2 
39 release upon cartilage injury was not influenced by levels of TSG-6. Cartilage degradation was 
40 significantly increased at 12 weeks post DMM in male TSG-6-/- mice, with a non-significant 
41 30% reduction in disease,  seen in TSG-6tg mice. No differences were observed in cartilage 
42 repair between genotypes. TSG-6 overexpression was unable to prevent accelerated OA in 
43 FGF2-/- mice.
44  
45 Conclusion: TSG-6 influences early gene regulation in the destabilised joint and exerts a 
46 modest late chondroprotective effect. Although strongly FGF2 dependent, TSG-6 does not 
47 explain the strong chondroprotective effect of FGF2.
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48 INTRODUCTION
49 Tumour necrosis factor alpha (TNF-α) stimulated gene 6 (TSG-6) is a secreted product of TNF-
50 α treated cells (1), which encodes for a 35kDa multifunctional protein, consisting of Link and 
51 CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor and bone 
52 morphogenetic protein 1) modules (2-4). TSG-6 is expressed in response to a range of pro-
53 inflammatory mediators (1, 2, 5) and is involved in a number of physiological processes 
54 including cervical ripening (6) and ovulation (7). 
55 In murine models of inflammatory arthritis, TSG-6 has been shown to protect the joint against 
56 damage. Delivery of recombinant protein led to a reduction in proteoglycan-induced arthritis 
57 while deletion of TSG-6 in the same murine model led to increased severity of arthritis (8, 9). 
58 Chondroprotection was seen in mice overexpressing TSG-6 in a collagen-induced arthritis 
59 model (10) and in antigen-induced arthritis where mice expressing a cartilage-specific 
60 transgene of TSG-6 had reduced aggrecan and cartilage degradation (11). 
61 TSG-6 has been detected at high levels in the synovial fluid of patients with rheumatoid arthritis 
62 and osteoarthritis (12, 13) and TSG-6 levels are also highly elevated in human synovial fluid 
63 following joint injury (14). Moreover, TSG-6 enzymatic activity, detected by the transfer of 
64 heavy chains from inter-alpha-inhibitor (IαI) to hyaluronan, has been identified as a biomarker 
65 for knee OA progression, such that increased TSG-6 activity is associated with a higher risk of 
66 total knee replacement (15). 
67 We have previously shown that TSG-6 is strongly regulated in the mouse joint early following 
68 surgical destabilisation of the medial meniscus (DMM), a model of OA. This regulation was 
69 deemed to be highly mechanosensitive as regulation was abrogated if the mice were prevented 
70 from mobilising on their destabilised joint (16). We also showed that both in vivo and in vitro 
71 injury-induced regulation of TSG-6 was strongly dependent on fibroblast growth factor 2 
72 (FGF2), a growth factor that is released from the cartilage matrix upon injury or loading (17, 
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73 18). Our previous work showed that mice deficient in FGF2 develop markedly accelerated OA 
74 upon surgical joint destabilisation and upon ageing, indicating a chondroprotective role for 
75 FGF2 in vivo (19). FGF2 may be chondroprotective through its ability to suppress ADAMTS5, 
76 one of the principal pathogenic aggrecan degrading enzyme in cartilage. Indeed, Adamts5 was 
77 elevated in FGF2-/- mice and FGF2 was able to suppress IL-1 induced aggrecanase activity, in 
78 human articular cartilage explants in vitro (20). Whether this is a direct response or whether 
79 suppression of ADAMTS5 is through an intermediate protein such as TSG6, is unknown.
80 In view of the strong anti-inflammatory role of TSG6 in other arthritis models, and its strong 
81 FGF2-dependent gene regulation, in this paper we explore the hypothesis that the 
82 chondroprotective properties of FGF2 may in part be mediated through TSG-6. We examine 
83 the course of disease after deletion or overexpression of TSG-6 and ask whether TSG-6 
84 overexpression is able to prevent accelerated disease that is seen in FGF2-/- mice.  
85
86 MATERIALS AND METHODS
87 Animals. Animal experiments were carried out after gaining ethical approval in agreement 
88 with local policy. 4-6 mice per cage were housed at 21°C in standard individually ventilated 
89 cages, maintained under a 12 hour light/dark cycle. Mice were fed a certified mouse diet (RM3; 
90 Special Dietary Systems) and water ad libitum. TSG-6 constitutive knockout (TSG-6-/-) and 
91 cartilage specific (Col2 driven, Balb/c background) constitutive over-expressing TSG-6 
92 transgenic mice (TSG-6tg) (11) were obtained from Katalin Mikecz, Rush University Medical 
93 Center, Illinois, USA. TSG-6-/- animals were backcrossed onto a C57BL/6 background (for 9 
94 generations) and were bred as heterozygotes to generate wildtype and knockout littermate 
95 controls. FGF2-/- mice were originally purchased from Jackson Laboratory and were 
96 backcrossed onto a pure C57BL/6 background (9 generations). TSG-6tg (Balb/c) mice were 
97 crossed with FGF2-/- (C57BL/6) to generate mixed litters of FGF2-/-;TSG-6tg and FGF2-/-;TSG-
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98 6WT (mixed background). Balb/c mice were obtained from Charles Rivers, UK laboratory. 
99 Figure 1 shows the schematic of the experiment design which summarized the in vivo 
100 experiments performed including a total number of mice of each genotype in each experiment.
101 Surgical induction of OA. 10 week old mice were anesthetized by inhalation of Isoflurane 
102 (3% induction and 1.5-2% maintenance) in 1.5-2 L/min oxygen. Following surgery, mice 
103 received a subcutaneous injection of Vetergesic (Alstoe Animal Health Limited). The mice 
104 were fully mobile 5 minutes after withdrawal of isoflurane. OA was induced by cutting the 
105 medial menisco-tibial ligament as previously described (16). For sham surgeries, the joint was 
106 opened under anaesthesia but the menisco-tibial ligament was left intact. Murine joints were 
107 harvested, and the skin and muscle bulk removed (16).
108 Histological assessment. Dissected knees were fixed in 10% formalin, decalcified in dilute 
109 formic acid, and embedded in paraffin. Coronal sections through the whole joint (80 µm apart) 
110 were cut and stained with Safranin O. Severity of cartilage destruction was assessed by a 
111 modified Osteoarthritis Research Society International OA grading system as previously 
112 described (19) by 2 blinded, independent scorers. At least 8 sections were evaluated per joint. 
113 Results were expressed as the summed score, which is calculated by adding the 3 highest scores 
114 together from any given joint section (all four joint compartments). Osteophytes were scored 
115 by size (0-3) and maturity (0-3) (n = 5 per group) as previously described by Little et al (21).   
116 Focal cartilage injury and histological assessment. Focal cartilage injury was carried out 
117 under a dissection microscope as previously described by Eltawil et al (22). Briefly, the joint 
118 was opened, the patella was dislocated and a longitudinal full thickness injury was made in the 
119 patellar groove using the tip of a 25 G needle. Patellar dislocation was reduced and the joint 
120 capsule and skin were sutured closed. The contralateral knee was left as an un-operated control. 
121 Three transverse sections at 100 µm intervals (22) were scored for cell morphology (0-4), 
122 matrix staining (0-4), filling of the defect (0-4), and osteochondral junction repair (0-2) 
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123 according to the modified Pineda scale; a high score indicating better cartilage repair (scores 
124 were inverted in Eltawil et al (22)). Sums of these 4 categories were given for each section and 
125 an average score was calculated (max score = 14). 
126 Cartilage injury. Mice (5–6 weeks old) were culled by CO2, and the acetabulofemoral (hip) 
127 joints were exposed by blunt dissection. The femoral cap (cartilage) was avulsed using forceps, 
128 as described previously (19). Murine hip cartilage was avulsed (avulsion injury) directly into 
129 serum-free Dulbecco's Modified Eagle's Medium (DMEM) and incubated for 48 h.  Some 
130 explant were rested for 48 h after avulsion, then either re-cut (cut with a scalpel into 4 pieces) 
131 or treated with FGF2 (250ng/ml) in fresh DMEM and left for 4 h prior to RNA extraction. For 
132 FGF2 release cartilage explants (post avulsion) were immediately placed in 100 µl serum-free 
133 DMEM at 370C for 30 min.  The medium collected (injury conditioned medium), was stored 
134 at -800C until FGF2 measurement.  
135 FGF2 measurement in cartilage avulsion injury conditioned medium.  FGF2 levels in the 
136 injury conditioned medium were assayed in duplicate on single spot ultra-sensitive V-PLEX 
137 bFGF kit (catalog no. K151MDD) from Meso Scale Discovery (MSD, Meso Scale Discovery, 
138 1601 Research Blvd, Rockville, MD). The assay was carried out according to the 
139 manufacturer’s instructions. Plates were read using MSD SPECTOR Imager 2400 measuring 
140 electrochemiluminescence. FGF2 concentrations were extrapolated from a standard curve 
141 calculated using a four-parameter logistic fit using MSD Discovery Workbench software 
142 version 3.
143 RNA extraction and Real-Time PCR. Four murine femoral heads were snap frozen and 
144 stored at -80°C. For whole joints, the joint was harvested at defined anatomical positions 
145 (patella insertion on tibia and quadriceps insertion on femur), and the skin and muscle removed 
146 as previously described (23). The femoral head cartilage or joints were pulverized using a 
147 PowerGen 125 Polytron instrument (Fisher Scientific), and RNA was extracted using Qiagen 
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148 RNeasy Mini Kit according to the manufacturers’ instructions. RNA was reverse transcribed 
149 using a High Capacity cDNA kit (Applied Biosystems) and analysed on 384-well custom-made 
150 TaqMan microfluidic cards.
151 Statistical analysis. Differences in gene expression levels between WT (C57BL/6) and TSG-
152 6-/- joints were analysed by unpaired multiple t-tests and the p-values corrected for multiplicity 
153 (q-values) using a family wise false discovery ratio of 5%. q-values are used in Table 1. 
154 Analysis of variance (ANOVA) with Sidak post hoc testing to adjust for multiplicity was used 
155 to compare TSG-6 gene expression differences between WT and FGF2-/- joints. Mann-Whitney 
156 U test was used to analyse TSG-6-/- and TSG-6tg histological pathology scores. Where three 
157 genotypes were considered side by side (Figure 5), ANOVA was performed. p values less than 
158 0.05 were considered statistically significant. Spearman r correlation test was used to assess a 
159 relationship between fold gene expression and histological score. Where data was  not normally 
160 distributed (tested using the D’Agostino normality test), and in the case of non-parametric data 
161 like osteophyte and focal cartilage data, Mann Whitney tests were used. Statistical testing was 
162 performed using GraphPad Prism 7 and SPSS 26.0 (IBM) software. 
163
164 RESULTS
165 TSG-6 is induced upon injury in an FGF2-dependent manner. We first confirmed TSG-6 
166 regulation following cartilage injury in vivo and in vitro as previously shown by our group (23). 
167 TSG-6 was strongly induced upon re-cutting injury or FGF2 stimulation (Figure 2a). It was 
168 also strongly upregulated in whole joints after DMM in an FGF2-dependent manner (Figure 
169 2b); upregulation of TSG-6 being suppressed in FGF2-/- mice. 
170
171
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172 Deletion of TSG-6 leads to increased inflammatory genes and decreased FGF2-dependent 
173 gene regulation following DMM. We next wanted to see how TSG-6 influenced the regulation 
174 of inflammatory response genes in the whole joint following DMM. TaqMan microfluidic 
175 cards were prepared for a number of known inflammatory and FGF2-dependent genes 
176 previously found to be upregulated in whole joints following DMM or after in vitro cartilage 
177 injury (16, 17). Twenty-eight genes were significantly regulated at any point post-surgery 
178 compared with the 0 hour unoperated controls. 15 genes (Table 1) were significantly 
179 upregulated in TSG-6-/- joints compared with WT (C57BL/6) joints 6 hours after DMM, 
180 including inflammatory response genes such as Adamts5, Ccl2 and IL-1α. These findings 
181 appear consistent with published studies showing an anti-inflammatory effect of TSG-6. 6 
182 genes were significantly suppressed in TSG-6-/- joints compared with WT (C57BL/6) joints 6 
183 hours after DMM including Inhibin βA, Tnfrsf12a, Podoplanin and Timp1. Interestingly, 5 out 
184 of the 6 genes that were strongly suppressed in TSG-6-/- joints had previously been shown to 
185 be highly FGF2 dependent in vivo and in vitro (17).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
186 Male TSG-6-/- show a modest late increase in disease following DMM. Gene expression 
187 profiles suggested an increase in inflammatory mediators in the joint associated with a 
188 reduction of FGF2-dependent genes. As FGF2 has been shown to be chondroprotective (19) 
189 we hypothesised that TSG-6-/- mice might develop accelerated OA following DMM. We 
190 examined the susceptibility of 10-week-old male and female WT (C57BL/6) and TSG-6-/- mice 
191 to DMM-induced OA and compared the summed scores 8 and 12 weeks after surgery. No 
192 differences were seen between TSG-6-/- and WT (C57BL/6) mice in either males or females at 
193 8 weeks post DMM (Figure 3a-b). At 12 weeks post DMM, TSG-6-/- male mice, but not female 
194 mice, had a statistically significant 50% increase in mean disease score (21.9 ± 10.1) compared 
195 with WT (C57BL/6) DMM controls (14.2 ± 4.7) (Figure 3a). No disease was seen in the 
196 contralateral joints (of DMM operated mice) of either genotype at either time point. 
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197 Osteophytes are established early (from 1 week) post DMM (24). At 8 weeks post DMM, there 
198 were no significant changes in osteophyte size or maturity in male mice (Figure 3c-d). This 
199 was also the case at 12 weeks (data not shown).
200 Male transgenic mice show a non-significant 30% reduction in disease. We next examined 
201 the susceptibility of male and female TSG-6tg mice following DMM. Cartilage degradation 
202 was assessed by histology 8 and 12 weeks after DMM. Male TSG-6tg mice showed a 30% 
203 reduction in mean disease score at 12 weeks post DMM that did not reach statistical 
204 significance after correcting for multiple testing (p = 0.066, Mann-Whitney U test) (Figure 4a). 
205 No differences were observed in sham-operated joints between genotypes at either 8 or 12 
206 weeks post surgery. There were no significant differences between any of the female 
207 experimental groups (Figure 4b). As male mice showed a non-significant reduction in disease 
208 mean score at 12 weeks post DMM, we looked at the amount of transgene expressed and 
209 whether this correlated with the cartilage degradation score. There was no correlation between 
210 the amount of transgene expressed (in the contralateral joint) and the severity of cartilage 
211 damage 12 weeks post DMM (Figure 4c). Nor was there a difference in osteophyte size or 
212 maturity in male mice 8 weeks post DMM (Figure 4d-e). 
213 In order to see whether TSG6 might be mediating the protection afforded by FGF2, we tested 
214 whether overexpression of TSG-6 would compensate for loss of FGF2. TSG-6tg mice were 
215 crossed with FGF2-/- mice to generate mixed litters of FGF2-/-;TSG-6tg and FGF2-/-;TSG-6WT 
216 mice (on a mixed background). Deletion of FGF2 (FGF2-/-;TSG-6WT) led to severe disease 
217 compared with wild type C57BL/6 or Balb/c mice consistent with our previous publication 
218 (19). Overexpression of TSG-6 (FGF2-/-;TSG-6tg) was unable to compensate for loss of FGF2 
219 (Figure 4f-g) and disease scores did not correlate with transgene level (Figure 4h).
220 Overexpression of TSG-6 does not affect healing of focal cartilage defects. 
221 Chondroprotection may be mediated by enhanced cartilage repair within the joint. We 
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222 considered whether TSG-6 affected the bioavailability of FGF2, a repair cytokine, after 
223 articular cartilage injury, and whether overexpression of TSG-6 would influence the healing of 
224 cartilage in vivo. To address the former, conditioned medium from injured mouse hips from 
225 FGF2-/-, WT(Balb/c), TSG-6+/-(heterozygotes), TSG-6-/- (homozygotes), and TSG-6tg mice 
226 were assayed for FGF2 (Figure 5a). Levels of FGF2 were equivalent between groups (apart 
227 from that generated by FGF2-/- cartilage). These results suggested that the bioavailability of 
228 FGF2 after injury was not determined by TSG-6 levels. Next, we generated full thickness 
229 defects in the patellar groove of TSG-6tg, WT (Balb/c) and C57BL/6 mice using a model of 
230 cartilage regeneration that has been shown to be strain and age-dependent (22). 10-week-old 
231 male and female Balb/c mice produced superior repair compared with C57BL/6 controls 8 
232 weeks after surgery (Figure 5c-d). No difference in repair was seen between TSG-6tg and WT 
233 (Balb/c) in either male or female mice.   
234   
235 DISCUSSION
236 TSG-6 mRNA is strongly upregulated post DMM and has a major influence on suppressing 
237 inflammatory genes as well as influencing FGF2-dependent genes early following induction of 
238 OA. In vivo data demonstrated increased cartilage degradation 12 weeks post DMM in male 
239 TSG-6-/- mice and a non-significant 30% reduction of mean disease score in TSG-6tg mice at 
240 the same time point (12 weeks). These data collectively suggest that TSG-6 has a real, albeit 
241 modest chondroprotective role in the joint. Despite its strong FGF2 dependence, TSG6 
242 overexpression appeared to be unable to reverse accelerated disease seen in FGF2-/- mice 
243 indicating that it is not the principal driver of FGF2-dependent chondroprotection.  It was 
244 possible that the increase in mRNA did not translate to an increase in protein but we were 
245 unable to validate this by immunohistochemistry (data not shown). When we considered 
246 gender, female mice developed very modest disease post DMM, as previously shown (25). 
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247 Little disease progression was seen over time in these mice and there was no detectable effect 
248 of genotype. 
249 The function of TSG-6 remains poorly understood and it remains unclear whether modest joint 
250 protection is afforded by its anti-inflammatory or other actions. The anti-inflammatory actions 
251 of TSG-6 may be related to the ability of the Link module of TSG-6 to bind to chemokines 
252 from the CXC and CC families (26) inhibiting neutrophil migration (27-29) or interfering with 
253 their matrix binding partners, heparin and heparan sulfate (HS) (30, 31). Murine OA induced 
254 by DMM is characterised by transient synovitis apparent immediately post-surgery but little 
255 overt neutrophilic infiltration is seen beyond 2 weeks (Vincent unpublished data). We did not 
256 attempt to measure levels of inflammatory cells in the OA joints, although there were increases 
257 in leukocyte markers such as CD14 and CD68 in whole joint extracts of TSG-6-/- compared 
258 with WT (C57BL/6) animals early post DMM. Nor did we specifically assess synovitis by 
259 histological scoring as this is difficult to do using coronal joint sections. Other inflammatory 
260 genes that were up-regulated in the TSG-6-/- joints included cytokines such as Il1α, Ccl2 and 
261 Il6. Although these molecules have proposed pro-catabolic actions in the joint, they are 
262 probably being made by non-leukocytic cells e.g. chondrocytes, and published, as well as 
263 unpublished data from our group, do not support a role for these molecules in driving disease 
264 (32, 33). If TSG-6 is not acting by inhibiting leukocyte migration to suppress OA, it may be 
265 controlling cartilage loss by down-regulating the protease network (34, 35). This is partly 
266 mediated by the formation of a complex between the Link module of TSG-6 with inter-alpha-
267 inhibitor (IαI) (36), a serine protease inhibitor. The inhibitory effect of this complex is specific 
268 for plasmin, a key activator of several MMPs, that is induced in murine OA by direct 
269 mechanical injury (16). 
270 Our data show that TSG-6 promotes several FGF2-dependent genes with putative anti-
271 inflammatory/repair functions e.g. the tissue inhibitor of metalloproteinase, Timp1 and inhibin 
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272 βA, the dimer of which forms activin A (a TGFβ family member). These genes are strongly 
273 induced in vivo and in vitro upon cartilage injury (17) and have purported chondroprotective 
274 actions by anti-catabolic and pro-repair roles. The fact that they are also TSG-6 dependent 
275 suggests either that TSG-6 can influence these genes directly (by an unknown mechanism), or 
276 that TSG-6 affects the regulation or bioavailability of FGF2. We speculated that TSG-6 could 
277 be influencing the binding of FGF2 in the pericellular matrix of cartilage, where it resides and 
278 is released upon tissue injury (37, 38). However, the latter did not appear to be the case as the 
279 release of FGF2 upon cartilage injury was not influenced by the level of TSG-6 expression. 
280 Other complex actions of TSG-6 have been described such as heavy chain transfer-mediated 
281 stabilisation of the ECM (39, 40) and interference of tissue derived morphogenetic proteins 
282 such as BMP2 (41), which could possibly account for the influence that we are describing. 
283 In the past decade, interest has turned to the role of TSG-6 in mesenchymal stem cells (MSCs); 
284 secreted TSG-6 is thought to mediate their immunomodulatory and tissue-protective properties 
285 (42, 43). TSG-6, as well as FGF2, regulate morphology and crucial cellular processes for the 
286 maintenance of stemness and biological properties of MSCs (44, 45). However, if the principal 
287 role of TSG-6 is to act on MSCs to enhance their repair capacity then we should have expected 
288 to see a change in repair score after focal cartilage injury. Our results show over-expression of 
289 TSG-6 has no influence on this repair. The focal cartilage injury model has not previously been 
290 explored in Balb/c mice and shows that this strain repairs well, in a similar fashion to DBA/1 
291 mice (22). To fully exclude a pro-repair action of TSG-6, it would be necessary to perform the 
292 focal cartilage defect in transgenic mice back-crossed onto a non-repairing strain such as 
293 C57BL/6. This is beyond the scope of the current project.
294 TSG-6 activity, measured by heavy chain transfer, has been described as a biomarker for 
295 disease progression and is associated with increases in other inflammatory mediators including 
296 TIMP1, MMP3 and IL-6 (15, 46). Our data do not support a pro-disease role for TSG-6 in OA 
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297 suggesting that correlation with disease progression may be epiphenomenal rather than causal. 
298 This is probably also the case following an acute knee injury, where synovial fluid TSG-6 
299 levels follow a similar pattern to several other inflammatory response proteins (14), which in 
300 part reflects the severity of the injury. Despite considerable efforts by a number of groups, the 
301 precise mechanism of action of TSG-6 remains elusive and its therapeutic potential in OA, 
302 speculative.
303
304 Limitations:  
305 We did not perform in depth analysis of the bone in TSG-6-/- mice. Deletion of TSG-6 has been 
306 shown to influence bone microarchitecture by modulating both osteoblast and osteoclast 
307 function, which could potentially affect the biomechanical response in the joint following 
308 DMM (41, 47). This is unlikely to have influenced the TSG-6 overexpressing mice as 
309 overexpression was driven by Type II collagen in these mice and the effects should be more 
310 restricted to the articular cartilage. Neither did we perform synovitis scoring nor pain 
311 assessments on these mice. This was due to limitations imposed by coronal sectioning of the 
312 joints which we routinely perform for OA cartilage scoring. Due to poor breeding of Tsg6+/- 
313 (heterozygotes) we were limited by the number of animals available and did not perform sham 
314 operations in this strain or examine the effect of genotype with age, which in our experience 
315 requires very much larger numbers. We recognise, discussed above, the limitation of examining 
316 focal cartilage repair in Balb/c mice when they already appear to have moderately good 
317 intrinsic repair capability (not known at the start of our experiment). We also recognise the 
318 difficulties of trying to make conclusions from data that either just succeed or just fail to reach 
319 statistical significance after stringent correction for multiple testing. We powered this study to 
320 detect a 40% change in disease score between genotypes at any time point. A retrospective 
321 power calculation indicates that we needed four additional wild type mice (n=16 WT, n=20 
Page 13 of 27 ACR Open Rheumatology
14
322 TSG-6Tg, at 12 weeks post DMM) for the 30% reduction in disease to reach statistical 
323 significance. 
324
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465 Figure Legends
466 Figure 1. Summary of experiment design.
467
468 Figure 2. TSG-6 is regulated in an FGF2-dependent manner. (a) Regulation of TSG-6 gene 
469 expression by re-cutting injury or FGF2 stimulation of murine cartilage explants. Murine hip 
470 cartilage (from male animals) was avulsed (avulsion injury) directly into serum-free DMEM 
471 and incubated for 48 h. Rested cartilage was either re-cut (re-cut injury) or treated with FGF2 
472 (250ng/ml) in fresh DMEM and left for 4 h prior to RNA extraction. Each point represents the 
473 mRNA from 4 hips pooled. Tsg6 levels were expressed relative to Gapdh and normalized to 
474 the control.  (b) RNA was extracted from male wild type or FGF2-/- mouse joints (n=3) at 
475 specified times post DMM. Tsg6 mRNA levels were expressed relative to 18s and normalized 
476 to the WT 0 h control. Statistical significance was determined by ANOVA with Sidak post hoc 
477 testing, comparing (a) treated compared with rested controls and (b) WT with FGF2-/- for each 
478 time point. 
479
480 Figure 3. Increased cartilage degradation in male TSG-6-/- mice 12 weeks post DMM. 
481 Histological chondropathy scores and representative histologic sections of knee cartilage 8 or 
482 12 weeks after DMM in (a) male and (b) female WT (C57BL/6) and TSG-6-/- mice. Black 
483 arrows in the images indicate cartilage defects. Scale bar = 200 µm. Statistical significance was 
484 determined by Mann Whitney U tests. Mean osteophyte scores: (c) size and (d) maturity in WT 
485 (C57BL/6) and TSG-6-/- male mice 8 weeks post DMM. Also shown are contralateral joint 
486 controls. CL-contralateral.
487
488 Figure 4. Joint pathology in TSGtg mice at 8 and 12 weeks post DMM. Histological 
489 chondropathy scores (left) and representative histologic sections (right) of knee cartilage 8 and 
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490 12 weeks after Sham or DMM in (a) male and (b) female TSG-6tg and WT (Balb/c) mice. Black 
491 arrows in the images indicate cartilage defects. Scale bar = 200 µm. Statistical significance was 
492 determined by Mann Whitney U tests. There were no significant differences seen between any 
493 of the female experimental groups by Two-way-ANOVA. (c) Fold increase of Tsg6 over WT 
494 transgene (by RT-qPCR) was plotted against summed cartilage score for male mice 12 weeks 
495 post DMM. R squared correlation statistical analysis was performed. Mean osteophyte scores: 
496 (d) size and (e) maturity, were carried out in WT (Balb/c) and TSG-6tg male mice 8 weeks after 
497 DMM. (f) Histological scores (left) and (g) representative histologic sections (right) of knee 
498 cartilage 8 weeks after DMM in male WT(C57BL6), FGF2-/-;TSG-6tg and FGF2-/-;TSG-6WT 
499 mice. Balb/c histology scores are derived from Figure 4a. Statistical significance was 
500 determined by One-way ANOVA with Sidak post hoc testing. (h) Level of Tsg6 expression 
501 was plotted against summed cartilage score for male FGF2-/-;TSG-6tg mice 8 weeks post DMM. 
502 R squared correlation statistical analysis was performed.
503
504 Figure 5. TSG-6tg mice do not have enhanced cartilage repair capacity. (a) FGF2 levels 
505 were measured by ELISA (MSD PLEX bFGF assay) in conditioned medium collected from 
506 injured mouse hips (a mixture of male and female) from WT(Balb/c), TSG-6tg, TSG-6+/- 
507 (heterozygotes), and TSG-6-/- (KO, homozygotes) mice. (b) Transverse section of the joint 
508 showing the position of patella groove. (c) Cartilage repair scores (left) and representative 
509 histological images of Safranin-O stained sections (right) 8 weeks after focal cartilage injury 
510 in male WT (Balb/c mice) TSG-6tg, and C57BL/6 mice, n = 6-12 mice per group. (d) Cartilage 
511 repair scores after focal cartilage injury in female WT (Balb/c) and TSG-6tg mice. Scale bar = 
512 200 µm. Mann Whitney U tests were used to determine statistical significance.
513
514 Table 1. Gene expression profiles of whole joint in TSG-6-/- and WT following DMM. 
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515 Subscript:The effect of TSG-6 deletion on relative mRNA levels for injury response genes in 
516 whole murine joints of WT (C57BL/6) and TSG-6-/- mice (n = 3 mice per group) 0 h, 6 h or 7 
517 days post DMM. Values are the mean fold change ± SEM. Results are expressed relative to 
518 18s. Statistical significance was determined using unpaired multiple t-tests and the p-values 
519 corrected for multiplicity (q-values) using a discovery ratio of 5%. Genes highlighted were 
520 shown to be significant (light grey = increase, dark grey = decrease). Adam – a disintegrin and 
521 metalloproteinase; Adamts – a disintegrin and metalloproteinase with thrombospondin motifs; 
522 Ctgf – connective tissue growth factor; F3 – coagulation factor III; Has1 - hyaluronan synthase 
523 1; Inhba - inhibin beta A; Nos – nitric oxide synthase; Pdpn- podoplanin; Ptges - prostaglandin 
524 E synthase; Ptgs2 -Prostaglandin-endoperoxide synthase 2; Sfrp2 - secreted frizzled-related 
525 protein 2; Timp1 – tissue inhibitor of metalloproteinase 1; Tnfrsf12a -tumor necrosis factor 
526 receptor superfamily member 12A (TWEAK  receptor); Wisp2 - WNT1-inducible-signaling 
527 pathway protein 2.
528
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             0h (Mean fold of change ± SEM)          6h/0h (Mean fold of change ± SEM)    7d/0h (Mean fold of change ± SEM)
Gene ID WT TSG-6-/- q value WT TSG-6-/- q value WT TSG-6-/- q value
Aggrecan 1.00 ± 0.06 1.03 ± 0.03 0.6424 0.89 ± 0.08 1.02 ± 0.12 0.4529 0.71 ± 0.02 0.81 ± 0.11 0.3972
Adam8 1.07 ± 0.17 1.11 ± 0.09 0.8616 2.41 ± 0.06 3.70 ± 0.33 0.018 1.31 ± 0.02 3.01 ± 0.24 0.0022
Adam9 1.12 ± 0.08 1.10 ± 0.09 0.8712 2.22 ± 0.07 2.84 ± 0.24 0.065 2.20 ± 0.11 1.47 ± 0.17 0.0232
Adamts1 0.98 ± 0.12 1.04 ± 0.05 0.6512 7.25 ± 1.54 2.40 ± 0.20 0.0351 3.10 ± 0.58 0.27 ± 0.04 0.008
Adamts15 0.98 ± 0.02 1.17 ± 0.09 0.1026 12.70 ± 0.65 13.54 ± 0.94 0.5087 7.34 ± 0.67 13.66 ± 0.71 0.0029
Adamts4 1.21 ± 0.12 1.14 ± 0.07 0.6099 3.90 ± 0.26 4.42 ± 0.34 0.2941 1.87 ± 0.22 2.19 ± 0.09 0.2514
Adamts5 1.17 ± 0.09 1.09 ± 0.11 0.6417 1.50 ± 0.13 3.10 ± 0.10 0.0006 1.57 ± 0.21 2.35 ± 0.15 0.042
Arginase 1 0.96 ± 0.10 0.82 ± 0.11 0.3997 84.23 ± 4.06 309.06 ± 32.50 0.0024 3.14 ± 1.05 317.81 ± 13.19 < 0.0001
Arginase 2 1.15 ± 0.12 1.20 ± 0.08 0.7661 1.05 ± 0.01 13.72 ± 0.89 0.0001 1.15 ± 0.09 13.29 ± 0.71 < 0.0001
Ccl2 1.09 ± 0.08 1.03 ± 0.02 0.494 131.41 ± 10.93 239.79 ± 8.64 0.0015 20.90 ± 0.64 29.31 ± 2.56 0.0332
Ccl5 1.03 ± 0.02 1.19 ± 0.12 0.2392 1.52 ± 0.07 1.97 ± 0.06 0.0081 0.73 ± 0.30 2.21 ± 0.81 0.163
Ccl7 0.96 ± 0.03 1.04 ± 0.03 0.1759 5.57 ± 1.93 10.04 ± 2.48 0.228 2.33 ± 0.29 18.31 ± 2.68 0.0041
Ccr2 0.75 ± 0.14 0.98 ± 0.46 0.654 1.11 ± 0.04 1.21 ± 0.10 0.4285 1.41 ± 0.26 2.38 ± 0.64 0.2298
Ccr5 1.21 ± 0.11 1.04 ± 0.16 0.428 3.50 ± 0.15 11.44 ± 0.79 0.0006 1.32 ± 0.15 19.71 ± 3.24 0.0048
Cd14 0.94 ± 0.16 1.09 ± 0.19 0.5612 5.16 ± 0.72 8.34 ± 0.51 0.0228 1.89 ± 0.51 2.90 ± 0.12 0.1236
Cd68 1.12 ± 0.34 0.65 ± 0.10 0.252 2.14 ± 0.05 4.98 ± 0.90 0.0345 1.35 ± 0.17 3.18 ± 0.33 0.0083
Col2a1 1.11 ± 0.09 1.10 ± 0.03 0.9419 0.31 ± 0.04 0.43 ± 0.17 0.5567 0.19 ± 0.04 0.34 ± 0.12 0.3177
Ctgf 0.74 ± 0.21 0.27 ± 0.13 0.1327 0.20 ± 0.05 0.35 ± 0.12 0.3289 0.17 ± 0.04 0.44 ± 0.18 0.2205
F3 1.10 ± 0.09 1.00 ± 0.14 0.6016 1.13 ± 0.09 12.94 ± 0.25 < 0.0001 2.14 ± 0.14 2.82 ± 0.13 0.0224
Has1 1.21 ± 0.11 1.15 ± 0.18 0.7819 3.73 ± 0.26 8.70 ± 0.55 0.0013 0.57 ± 0.29 3.07 ± 0.87 0.052
Has2 1.08 ± 0.08 1.05 ± 0.04 0.7588 2.04 ± 0.04 3.24 ± 0.69 0.1542 2.35 ± 0.34 2.64 ± 0.10 0.4547
Il1a 1.07 ± 0.04 1.04 ± 0.03 0.5471 1.21 ± 0.06 2.71 ± 0.09 0.0002 1.02 ± 0.01 2.51 ± 0.22 0.0026
Il1b 1.00 ± 0.00 1.16 ± 0.08 0.1215 5.17 ± 0.16 5.31 ± 0.65 0.8441 1.92 ± 0.21 2.77 ± 0.56 0.2268
Il1r1 1.18 ± 0.12 0.86 ± 0.19 0.2308 3.65 ± 0.39 7.07 ± 0.42 0.0039 1.31 ± 0.04 2.24 ± 0.35 0.0559
Il1rl1 1.03 ± 0.02 1.21 ± 0.10 0.1517 2.02 ± 0.16 2.11 ± 0.15 0.6776 1.47 ± 0.22 1.45 ± 0.18 0.9486
Il33 1.09 ± 0.05 1.30 ± 0.01 0.0127 3.20 ± 0.26 5.48 ± 0.32 0.0052 1.70 ± 0.35 4.53 ± 0.09 0.0014
Il6 1.25 ± 0.13 1.16 ± 0.25 0.7802 16.84 ± 1.67 50.02 ± 11.37 0.0447 0.99 ± 0.33 123.72 ± 14.94 0.0012
Inhba 1.06 ± 0.17 0.82 ± 0.09 0.2862 2.73 ± 0.05 0.93 ± 0.27 0.0027 0.70 ± 0.26 0.82 ± 0.09 0.6733
Mmp13 0.96 ± 0.02 1.50 ± 0.33 0.1815 0.42 ± 0.04 4.48 ± 1.67 0.0721 0.61 ± 0.24 6.92 ± 2.29 0.0519
Mmp19 1.17 ± 0.11 0.93 ± 0.23 0.3946 3.36 ± 0.25 3.56 ± 0.11 0.5015 1.82 ± 0.20 5.86 ± 1.68 0.0756
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Mmp3 1.36 ± 0.18 1.26 ± 0.26 0.7757 6.01 ± 0.00 3.21 ± 0.30 0.0008 2.01 ± 0.00 9.84 ± 0.34 < 0.0001
Mmp8 1.19 ± 0.05 1.03 ± 0.01 0.0286 2.04 ± 0.02 3.69 ± 0.82 0.1137 1.01 ± 0.00 3.43 ± 1.25 0.125
Nos2 1.00 ± 0.00 1.16 ± 0.14 0.3365 14.73 ± 1.86 25.34 ± 3.53 0.0566 8.18 ± 0.74 21.75 ± 1.83 0.0023
Pdpn 0.97 ± 0.15 0.98 ± 0.19 0.9671 6.87 ± 0.22 2.09 ± 0.82 0.0048 2.30 ± 0.21 1.38 ± 0.16 0.0256
Ptges 0.85 ± 0.15 1.20 ± 0.08 0.1083 1.37 ± 0.09 1.99 ± 0.01 0.0021 1.25 ± 0.25 2.58 ± 0.40 0.0495
Ptgs2 1.09 ± 0.06 1.05 ± 0.01 0.5115 14.40 ± 1.41 21.76 ± 2.12 0.0443 9.04 ± 1.05 23.83 ± 2.28 0.0042
Sfrp2 0.92 ± 0.19 1.05 ± 0.02 0.5473 0.58 ± 0.22 2.93 ± 0.56 0.0171 3.11 ± 0.45 3.44 ± 0.37 0.5949
Timp1 0.93 ± 0.09 0.44 ± 0.01 0.0068 4.90 ± 0.26 1.57 ± 0.04 0.0002 1.24 ± 0.16 1.78 ± 0.28 0.1737
Tnfrsf12a 1.05 ± 0.07 0.83 ± 0.14 0.243 5.83 ± 0.30 1.08 ± 0.15 0.0001 2.58 ± 0.23 1.12 ± 0.12 0.0047
TSG-6 1.14 ± 0.14 31.19 ± 0.13 45.27 ± 1.17
Wisp2 0.96 ± 0.05 1.09 ± 0.07 0.1775 7.03 ± 0.24 6.66 ± 0.47 0.5142 4.24 ± 0.23 3.08 ± 0.29 0.034
Wnt16 0.92 ± 0.11 0.88 ± 0.10 0.7704 0.95 ± 0.04 0.44 ± 0.03 0.0007 0.79 ± 0.15 0.73 ± 0.17 0.8061
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